WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human…
One of the hallmarks of cancer is the ability to avoid detection by the immune system. Cancer cells get selected…
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite…
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to…
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated…
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T…
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients…
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive…
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other…